Management of liver failure in a haemophilic patient co-infected with human immunodeficiency and hepatitis C viruses.
We present a case of liver failure in a haemophilic patient coinfected with transfusion acquired human immunodeficiency (HIV) and hepatitis C (HCV) viruses. The case illustrates the interaction of multiple viruses with accelerated progression to end stage liver disease and ultimately death. We report the impact on the patient management of two liver biopsies, which diagnosed an initial drug induced hepatitis and subsequently an atypical HCV related hepatitis.
Nitu
I C
IC
Haemophilia Centre, Royal Free and University College Medical School of University College London, UK.
Lee
C A
CA
Dhillon
A P
AP
Mistry
P K
PK
D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use; D019380:Anti-HIV Agents / Q000009:adverse effects / Q000627:therapeutic use; D017291:Clarithromycin / Q000009:adverse effects / Q000627:therapeutic use; D016049:Didanosine / Q000009:adverse effects / Q000627:therapeutic use; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D006467:Hemophilia A / Q000150:complications* / Q000188:drug therapy; D016174:Hepacivirus / Q000302:isolation & purification*; D006526:Hepatitis C / Q000150:complications*; D006801:Humans; D017114:Liver Failure, Acute / Q000209:etiology* / Q000503:physiopathology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D015215:Zidovudine / Q000009:adverse effects / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D019380:Anti-HIV Agents; D015215:Zidovudine; D017291:Clarithromycin; D016049:Didanosine